Moderna (MRNA) Stock Falls 18% After Melanoma Trial Data Leaks Early

TLDR Moderna (MRNA) closed Thursday at $202.63, down 18%, after trial data leaked early. It fell as much as 26% during the day. Merck confirmed the leak. The vaccine plus Keytruda cut the risk of recurrence or death by 42%. More than $17 billion in market value disappeared. The stock had nearly quadrupled since mid-August. Support sits near $174, with $116 the next level below. The stock was down 3% in premarket Friday. Full data is due Saturday in Madrid. Moderna (MRNA) stock closed Thursday at $202.63, down 18%. The drop was its biggest intraday fall on record, at one point reaching 26%. Moderna, Inc., MRNA Results from a late-stage melanoma trial leaked online before their planned debut. Merck, Moderna’s partner, confirmed the data came out early.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to CoinCentral.